Shares of Edgewise Therapeutics, Inc. (EWTX) are surging in premarket trading on Tuesday, up over 9% after the biopharmaceutical company reported better-than-expected earnings results for the third quarter of 2024.
For the quarter ended September 30, Edgewise reported a loss of $0.36 per share, narrowly beating analyst expectations of a $0.37 per share loss. The company did not generate any revenue during the quarter, which was in line with forecasts.
While Edgewise continues to operate at a loss as it develops its pipeline of therapeutics, the earnings beat has fueled investor optimism and driven the stock higher in premarket trading. The strong performance follows a 37.2% gain for EWTX shares during the third quarter and a remarkable 234.7% increase so far this year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。